July 2018
Volume 59, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2018
Luminescent porous silicon particles as a self-reporting intravitreal drug delivery system
Author Affiliations & Notes
  • Kristyn Huffman
    Ophthalmolgy, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Joanna Wang
    Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States
  • Ying Xiao
    Ophthalmolgy, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • William R Freeman
    Ophthalmolgy, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Michael J Sailor
    Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States
  • Lingyun Cheng
    Ophthalmolgy, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Kristyn Huffman, None; Joanna Wang, None; Ying Xiao, None; William Freeman, None; Michael Sailor, None; Lingyun Cheng, None
  • Footnotes
    Support  NIH EY020617, NIH P30EY022589, and Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4458. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kristyn Huffman, Joanna Wang, Ying Xiao, William R Freeman, Michael J Sailor, Lingyun Cheng; Luminescent porous silicon particles as a self-reporting intravitreal drug delivery system. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4458.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, there are no ocular drug delivery systems with the ability to report real-time drug concentrations. Retreatment is assessed by disease relapse. Treating the patient prior to disease recurrence can better preserve visual function. We are developing a reportable drug delivery system using luminescent porous silicon (pSi). The current study demonstrates the prototype of a self-reporting intravitreal luminescent pSi drug delivery system that is imaged using a simple infrared fundus camera fitted to a commercial fundus imaging system.

Methods : Luminescent pSi particles were fabricated with a pore size of 20nm and average particle size of 65µm. 3mg of particles suspended in PBS were injected into 4 eyes of 4 rabbits. After injection, the particles were monitored by indirect ophthalmoscope, IOP, Slit lamp, color fundus photos and infrared imaging over 8 months.

Results : No toxicity was seen during the entire study period. The vitreous depot of pSi particles was graded in relation to optic nerve size during indirect ophthalmoscope exams. The half-life of the pSi particles in the vitreous was 108 days. The infrared images revealed that the luminescent particle depot corresponds in shape and size to the visible light photographs taken. The intensity of emitted infrared from the luminescent pSi in the vitreous decreased over time. The shift in infrared wavelength over time was also recorded, which can be associated with payload release and real-time drug concentration in the vitreous.

Conclusions : Luminescent pSi particles in the vitreous can be imaged by an infrared camera adapted to a commercial fundus camera. These particles show promise as a long-lasting, self-reporting drug delivery system.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Color fundus and infrared images of the particle depot over time.

Color fundus and infrared images of the particle depot over time.

 

Degradation of particle depot size over time.

Degradation of particle depot size over time.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×